Peptides for Recovery & Joint Health: BPC-157 Explained
BPC-157 is one of the most-discussed recovery peptides. Here's what the research shows, what the 2026 FDA changes mean, and an honest look at the evidence gaps.
By Anthivera Editorial · Updated · 1 min read
Awaiting medical reviewDraft
Status: Stub. Outline is in place per
/docs/CONTENT-PLAN.md(Article 6).
What BPC-157 is#
Section content TBD. Synthetic 15-amino-acid peptide derived from a gastric-juice protein.
What the research actually shows#
Section content TBD. Strong preclinical (animal) data on tissue, tendon, and gut healing. Only ~3 small human studies.
The honest evidence gap#
Section content TBD. Say it plainly: no completed large human RCTs.
The 2026 regulatory rollercoaster#
Section content TBD. Category 2 (2023) → removed from Category 2 (April 2026) → PCAC review (July 2026). NOT yet formal Category 1; NOT FDA approval.
The WADA angle#
Section content TBD. Still banned for tested athletes regardless of FDA status.
Gray-market "research chemical" BPC-157#
Section content TBD. Why that route is risky and not the same as a compounded prescription.
What a cautious reader should do#
Section content TBD.